被忽视的真相:PGT-A宣传成功率夸大收益并低估潜在种植损失
该文指出PGT-A技术虽在胚胎遗传学理解上有进展,但被积极营销为成熟技术,夸大收益并低估潜在种植损失。营销材料自身数据亦显示大量潜在种植损失,缺乏证据基础。应为IVF患者提供准确循证咨询,选择性应用PGT-A。
要点
- PGT-A被营销为成熟技术,但技术仍处早期阶段。
- 营销夸大收益,低估PGT-A导致的潜在种植损失。
- 应选择性应用PGT-A,仅用于收益明确大于成本者。
核心结论
- PGT-A被宣传为成熟技术,但缺乏证据基础,夸大收益并低估潜在种植损失。
主要发现
- 营销材料自身数据亦显示大量潜在种植损失。
- PGT-A被营销为准确、错误极少且适用于所有IVF案例,但无证据支持。
临床怎么用
- 应为IVF患者提供准确循证咨询。
- 选择性应用PGT-A,仅用于收益明确大于成本者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The utilization of preimplantation genetic testing for aneuploidy (PGT-A) has understandable intuitive appeal in reassuring the clinician that 'everything possible' has been done to assure the birth of a healthy baby. Whereas the development of the PGT-A technology is still in a relatively early stage, great strides have nevertheless been made in the understanding of the genetics of the preimplantation human embryo. The problem lies not in the progress that has been achieved, but rather, in the reality that PGT-A is being actively marketed as a mature technology. Those that market the technology overstate its benefits and underestimate the losses of potential implantations that are the consequence of the practice of PGT-A. The implication is that the PGT-A technology is accurate, has minimal errors and is ready to be applied to every case of IVF. This approach is not evidence-based. Substantial losses of potential implantations are even evident in the analysis of the numbers presented by marketing materials themselves. In order to provide accurate, evidence-based counseling for patients undergoing IVF, we need to apply an appropriate level of scientific scrutiny to the data that are available and apply PGT-A selectively to those cases in which the benefits clearly outweigh the costs.
引用
- Paulson RJ. Hidden in plain sight: the overstated benefits and underestimated losses of potential implantations associated with advertised PGT-A success rates. Hum Reprod. 2020. PMID: 32100030. doi:10.1093/humrep/dez280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。